Latest Novartis Stories

Syngenta unveiled its new crop research facility during a grand opening celebration today at the company’s RTP Innovation Center. The first of its kind, $72 million Advanced Crop Lab allows company researchers to simulate any agricultural climate and precisely measure plant inputs – the key to helping farmers grow more food from fewer resources. RESEARCH TRIANGLE PARK, N.C., USA (PRWEB) May 17, 2013 •    First of its kind research facility...

Design Enables More Rapid Response to Potential Pandemics LA JOLLA, Calif. and ROCKVILLE, Md., May 15, 2013 /PRNewswire/ -- A team of international researchers from the J. Craig Venter Institute (JCVI), Synthetic Genomics Inc. (SGI), Novartis Vaccines and Diagnostics, the Biomedical Advanced Research and Development Authority (BARDA, US Department of Health and Human Services), and Institut fur Virologie, Phillips Universitat, has published a study detailing new methods to rapidly generate...

BOULDER, Colo., May 15, 2013 /PRNewswire/ -- Array BioPharma Inc. (NASDAQ: ARRY) today announced presentations on its MEK inhibitors, MEK162 (licensed to Novartis) and selumetinib (licensed to AstraZeneca) at the 2013 American Society of Clinical Oncology (ASCO) Annual Meeting, which will be held May 31 - June 4, 2013 in Chicago, Illinois. Both MEK inhibitors are expected to advance into Phase 3 trials in 2013: Novartis expects to evaluate MEK162 in NRAS- and BRAF-mutant melanoma...

BASEL, Switzerland and WILMINGTON, Delaware, May 14, 2013 /PRNewswire/ -- Syngenta and DuPont today announced technology licensing agreements that will broaden each company's crop protection product portfolio and enable both to bring new products to market more efficiently. Syngenta has obtained a global license from DuPont to develop products containing DuPont's fungicide oxathiapiprolin. The development of this new piperidinyl thiazole isoxazoline class of fungicides...

Ilaris® (canakinumab) is the first interleukin-1 beta inhibitor for the treatment of SJIA and the only treatment approved specifically for SJIA that is given as a monthly subcutaneous injection(1) EAST HANOVER, N.J., May 10, 2013 /PRNewswire/ -- Novartis announced today that the US Food and Drug Administration (FDA) has approved Ilaris(®) (canakinumab) for the treatment of active systemic juvenile idiopathic arthritis (SJIA) in patients aged 2 years and older. Ilaris is the...

BEDFORD, Mass., May 6, 2013 /PRNewswire/ -- Hologic, Inc. (Hologic or the Company) (NASDAQ: HOLX), a leading developer, manufacturer and supplier of premium diagnostics products, medical imaging systems and surgical products, with an emphasis on serving the healthcare needs of women, today announced its results for the second fiscal quarter ended March 30, 2013. Highlights of the Quarter Include: Financial: Revenues of $612.7 million, net of a $(6.4) million adjustment related...

-Targets difficult-to-treat patient population with few remaining options - BOULDER, Colo., May 6, 2013 /PRNewswire/ -- Array BioPharma Inc. (NASDAQ: ARRY) today announced that it will initiate a global Phase 3 clinical trial in patients with recurrent low-grade serous ovarian cancer (LGSOC) during the summer of 2013. The study, called MILO (MEK Inhibitor in Low Grade Serous Ovarian Cancer), will evaluate the efficacy and safety of MEK162 compared to standard chemotherapy...

U.S. government's intervention in two whistleblower lawsuits against Novartis, alleging kickbacks and other frauds, could have serious implications for the pharmaceutical giant, according to members of the Qui Tam Team. Philadelphia, PA (PRWEB) May 02, 2013 Qui Tam Team http://www.quitamteam.com; e-mail: QuiTamTeam(at)gmail(dot)com As highlighted in a piece by Jonathan Stempel of The Washington Post on April 26, 2013, following two federal lawsuits, including U.S. Attorney Preet...

BOZEN, Sud-Tirol, Italy, May 1, 2013 /PRNewswire/ -- Health Robotics today announced the appointment of Gordon Meyer to its Board of Directors. Mr. Meyer has more than 30 years' experience in the health care industry with Sandoz Canada (Novartis), C.R. Bard, Sabex, and Baxter Canada, amongst others. During the last sixteen years at Sabex and Sandoz-Novartis he led a team that is the Canadian leader in hospital small volume parenteral injectables. Mr. Meyer stated: "In...

BASEL, Switzerland, April 29, 2013 /PRNewswire/ -- Syngenta today acknowledged that European Union (EU) Member States for the second time failed to agree on the European Commission's proposal for a ban on neonicotinoid pesticides. The latest decision should compel the Commission to return to the negotiating table rather than forcing through the implementation of a ban. Syngenta Chief Operating Officer, John Atkin, said: "The European Commission has again failed to win...